New TPO treatment schedules of increased safety and efficacy: pre‐clinical validation of a thrombopoiesis simulation model

Summary.  Thrombopoietin (TPO) immunogenicity hampers its development as a therapeutic agent for attenuating thrombocytopenia and improving platelet harvest in donors. This work was aimed at validating, in mouse and in monkey experiments, a thrombopoiesis computer‐model prediction that platelet counts, similar to those obtained with accepted TPO dose scheduling, can also be achieved by new and safer schedules of significantly reduced doses. To this end we compared, in a two‐arm mouse experiment, platelet increases obtained with a single intraperitoneal dosing of recombinant mouse TPO (17·5 μg/kg), with those obtained by the model‐suggested protocol of a significantly reduced dose (2 μg/kg on 4 consecutive days). The two TPO regimens generated similar platelet profiles, peaking at ca. 2700 × 109/l platelets. In rhesus monkeys, treated by rhesus monkey recombinant TPO (5 μg/kg on 4 consecutive days), the suggested protocol yielded effective platelet stimulation with significantly reduced immunogenicity. The model's ability to predict individual monkey responses to several new TPO administration protocols was further validated, proving sufficient robustness in providing good predictions with limited input data. The simulation tool could be used for testing the effects of different therapeutic agents on thrombopoiesis. Human trials are warranted for testing the suggested improved TPO protocol, possibly in conjunction with chemotherapy.

[1]  G. Demetri,et al.  Targeted approaches for the treatment of thrombocytopenia. , 2001, The oncologist.

[2]  S. Hanson,et al.  Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. , 1996, Blood.

[3]  L. Feinendegen,et al.  Relative number and proliferation kinetics of hemopoietic stem cells in the mouse. , 1979, Blood cells.

[4]  D. Anderson,et al.  Algorithms for minimization without derivatives , 1974 .

[5]  T. Boone,et al.  Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. , 1995, Blood.

[6]  G. Wagemaker,et al.  The Efficacy of Single-Dose Administration of Thrombopoietin With Coadministration of Either Granulocyte/Macrophage or Granulocyte Colony-Stimulating Factor in Myelosuppressed Rhesus Monkeys , 1997 .

[7]  D. Srivastava,et al.  A single intravenous dose of murine megakaryocyte growth and development factor potently stimulates platelet production, challenging the necessity for daily administration. , 1998, Blood.

[8]  G. Senaldi,et al.  The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice. , 1999, Experimental hematology.

[9]  William H. Press,et al.  The Art of Scientific Computing Second Edition , 1998 .

[10]  R. Benjamin,et al.  Stimulation of Megakaryocyte and Platelet Production by a Single Dose of Recombinant Human Thrombopoietin in Patients with Cancer , 1997, Annals of Internal Medicine.

[11]  H. Miyazaki,et al.  In Vivo Effects of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor on Hematopoiesis in Normal Mice , 1996, Stem cells.

[12]  Charles G. Martin,et al.  Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Basser.  The impact of thrombopoietin on clinical practice. , 2002, Current pharmaceutical design.

[14]  Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. , 1995 .

[15]  Justus F. Mueller,et al.  The Blood Morphology of Laboratory Animals , 1968 .

[16]  Z. Agur,et al.  A NEW METHOD FOR PREDICTING AND OPTIMIZING THROMBOPOIETIN (TPO) THERAPEUTIC PROTOCOLS IN THROMBOCYTOPENIC PATIENTS AND IN PLATELET DONORS , 2001 .

[17]  G. Wagemaker,et al.  In vivo expansion of hemopoietic stem cells , 1998, Stem cells.

[18]  A. Hutson,et al.  Pharmacokinetics, Pharmacodynamics, and Safety of Administering Pegylated Recombinant Megakaryocyte Growth and Development Factor to Newborn Rhesus Monkeys , 1999, Pediatric Research.

[19]  P Ubezio,et al.  Increasing 1-beta-D-arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics. , 1994, Cancer research.

[20]  L. Harker.  Physiology and clinical applications of platelet growth factors. , 1999, Current opinion in hematology.

[21]  Zvia Agur,et al.  Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs , 1988 .

[22]  V. Broudy,et al.  Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. , 1996, Experimental hematology.

[23]  G. Wagemaker,et al.  The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys. , 1997, Blood.

[24]  M. Benekli,et al.  Thrombopoietin as a Drug: Biologic Expectations, Clinical Realities, and Future Directions , 2002, Clinical and applied thrombosis/hemostasis.

[25]  G. Wagemaker,et al.  Prevention of thrombocytopenia by thrombopoietin in myelosuppressed rhesus monkeys accompanied by prominent erythropoietic stimulation and iron depletion. , 1997, Blood.

[26]  R. Yeager,et al.  Pharmacokinetics and Hematological Effects of the PEGylated Thrombopoietin Peptide Mimetic GW395058 in Rats and Monkeys After Intravenous or Subcutaneous Administration , 1999, Stem cells.

[27]  Z Agur,et al.  Zidovudine toxicity to murine bone marrow may be affected by the exact frequency of drug administration. , 1991, Experimental hematology.

[28]  S. Hanson,et al.  Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. , 1996, Blood.

[29]  William H. Press,et al.  Numerical recipes in C. The art of scientific computing , 1987 .

[30]  G. Wagemaker,et al.  A single dose of thrombopoietin shortly after myelosuppressive total body irradiation prevents pancytopenia in mice by promoting short-term multilineage spleen-repopulating cells at the transient expense of bone marrow-repopulating cells. , 1998, Blood.

[31]  F. A. Seiler,et al.  Numerical Recipes in C: The Art of Scientific Computing , 1989 .

[32]  S. Ebbe,et al.  MEGAKARYOCYTOPOIESIS IN THE RAT. , 1965, Blood.

[33]  F. D. de Sauvage,et al.  Role of the Distal Half of the c-Mpl Intracellular Domain in Control of Platelet Production by Thrombopoietin In Vivo , 2000, Molecular and Cellular Biology.

[34]  J T Arnold,et al.  A single injection of pegylated murine megakaryocyte growth and development factor (MGDF) into mice is sufficient to produce a profound stimulation of megakaryocyte frequency, size, and ploidization. , 1997, Blood.